KARYOPHARM THERAPEUTICS INC (KPTIXXXX)
Institutional ownership reported to the SEC as of Q2 2026, across 30 quarters.
1
Reporting holders
$419.6K
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Birchview Capital, LP | $419.6K | 42,952 | 0.20% | 2q | -48.8%-$400.6K |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $419.6K | 42,952 | 0 | 0 | 1 | 0.0% |
| Q1 2026 | 1 | $467.6K | 83,952 | 1 | 0 | 0 | 0.0% |
| Q3 2025 | 1 | $183.0K | 27,985 | 0 | 0 | 0 | 0.0% |
| Q2 2025 | 1 | $120.6K | 27,985 | 0 | 0 | 0 | 0.0% |
| Q1 2025 | 2 | $1.3M | 352,017 | 0 | 0 | 2 | 0.0% |
| Q4 2024 | 81 | $39.3M | 57,840,728 | 10 | 19 | 16 | 0.4% |
| Q3 2024 | 85 | $47.9M | 57,453,546 | 7 | 16 | 28 | 0.6% |
| Q2 2024 | 107 | $58.0M | 66,267,447 | 25 | 22 | 30 | 0.9% |
| Q1 2024 | 105 | $111.2M | 73,247,514 | 17 | 33 | 27 | 0.5% |
| Q4 2023 | 109 | $60.5M | 69,581,748 | 20 | 21 | 36 | 0.6% |
| Q3 2023 | 107 | $97.7M | 72,351,145 | 13 | 34 | 27 | 0.8% |
| Q2 2023 | 122 | $135.8M | 75,439,060 | 26 | 41 | 36 | 0.5% |
| Q1 2023 | 109 | $322.3M | 82,709,428 | 18 | 41 | 26 | 0.4% |
| Q4 2022 | 123 | $297.2M | 87,058,799 | 25 | 50 | 28 | 0.6% |
| Q3 2022 | 145 | $367.8M | 66,705,622 | 18 | 59 | 38 | 1.0% |
| Q2 2022 | 147 | $306.8M | 67,144,724 | 26 | 36 | 57 | 1.3% |
| Q1 2022 | 139 | $513.2M | 68,287,325 | 22 | 40 | 44 | 2.2% |
| Q4 2021 | 144 | $366.3M | 54,962,060 | 25 | 49 | 45 | 3.8% |
| Q3 2021 | 135 | $343.6M | 57,409,957 | 14 | 56 | 34 | 2.7% |
| Q2 2021 | 154 | $625.5M | 58,986,418 | 22 | 52 | 54 | 2.7% |
| Q1 2021 | 170 | $641.5M | 60,160,677 | 26 | 56 | 51 | 0.7% |
| Q4 2020 | 169 | $1.0B | 64,231,597 | 25 | 61 | 42 | 2.1% |
| Q3 2020 | 159 | $960.1M | 65,148,336 | 28 | 54 | 54 | 0.9% |
| Q2 2020 | 157 | $1.3B | 69,827,041 | 41 | 64 | 31 | 1.2% |
| Q1 2020 | 141 | $1.3B | 68,055,036 | 25 | 54 | 40 | 2.5% |
| Q4 2019 | 150 | $1.2B | 59,782,075 | 44 | 40 | 40 | 2.0% |
| Q3 2019 | 109 | $568.5M | 58,482,928 | 25 | 39 | 26 | 1.0% |
| Q2 2019 | 105 | $318.8M | 52,044,159 | 18 | 37 | 28 | 2.2% |
| Q1 2019 | 110 | $304.2M | 51,356,214 | 20 | 40 | 21 | 1.1% |
| Q4 2018 | 116 | $488.1M | 51,971,137 | 2 | 4 | 1 | 0.3% |